




## Kinase Panel Screen



**ICE Bioscience INC**

**September 2019**

## **ICE-Kinase Panel Screen**

The Kinase panel service leverages a panel of 176 kinases covering AGC, CAMK, CMGC, CK1, STE, TK, TKL, lipid and atypical kinase families, plus important mutant forms. Kinase panel is an ideal choice for all stages of drug discovery and development, to identify the most selective drug candidates from the largest collection of wildtype kinase assays.


### **Services Available for Kinase Assays:**

- High throughput screening assays
- Large scale single dose, duplicate profiling services
- IC50 profiling services — 5 or 10 dose with curve fitting
- Ki determination assay services
- Custom Assay development
- Substrate determination assay
- Research collaboration


Detection Method: Activity Assay  
Turn Around Time: 8-10 Work Days

IC50 test was provided for all kinases, and E50 test was provided for some kinases. Please contact us for a detailed list of kinases!

ICE Kinase Panel: 174 kinases (marked with red spot) cover broad family members



# Example verified data:



[1]. [SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples. Cancer Chemother Pharmacol. 2009 Sep;64\(4\):723-32.](#)

[2]. [Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases. J Immunol. 2013. 191\(7\), 3568-3577.](#)

[3]. [Optimization of imidazo\[4,5-b\]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia. J Med Chem. 2012 Oct 25;55\(20\):8721-34.](#)

[4]. [Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol Cancer Ther. 2004 Nov;3\(11\):1427-38.](#)

[5]. [Peng SB, et al. Kinetic characterization of novel pyrazole TGF-beta receptor I kinase inhibitors and their blockade of the epithelial-mesenchymal transition. Biochemistry. 2005, 44\(7\), 2293-2304.](#)

Kinase List( I )			
ABL(ABL1)	CHK2(CHEK2)	FGR	MAP3K2
ABL1[F317I]	CK1 $\alpha$ (CSNK1A1)	FLT1 (VEGFR1)	MAP3K3
ABL1[T315I]	CK1 $\gamma$ 1 (CSNK1G1)	FLT3	MAP3K4
ACK(TNK2)	CK1 $\gamma$ 2 (CSNK1G2)	FLT3[D835Y]	MAP3K5(ASK1)
ACVR1B(ALK4)	CK1 $\gamma$ 3 (CSNK1G3)	FLT3[ITD]	MAPKAPK2
ACVRL1(ALK1)	CK1 $\delta$ (CSNK1D)	FLT4 (VEGFR3)	MARK3
AKT1	CK1 $\epsilon$ (CSNK1E)	FMS (CSF1R)	MER (MERTK)
AKT2	CK2 $\alpha$ 1/ $\beta$ (CSNK2A1/B)	FRK	MET
AKT3	CK2 $\alpha$ 2/ $\beta$ (CSNK2A2/B)	FYN [isoform a]	MET[D1228H]
ALK	CSK	FYN [isoform b]	MET[D1228N]
ALK[G1202R]	DAPK1	GSK3 $\alpha$ (GSK3A)	MET[Y1230A]
EML4-ALK	DCAMKL1	GSK3 $\beta$ (GSK3B)	MET[Y1230C]
ALK2(ACVR1)	DCAMKL2	HCK	MET[Y1230D]
AMPK $\alpha$ 1/ $\beta$ 1/ $\gamma$ 1	DDR1	HER2 (ERBB2)	MOS
ARG(ABL2)	DDR2	HGK(ZC1)	MST1 (STK4)
AurA (AURKA)	DYRK1A	HIPK1	MUSK
AurB (AURKB)/INCENP	DYRK1B	HIPK2	NEK1
AurC (AURKC)	DYRK2	HIPK3	NEK2
AXL	DYRK3	HIPK4	NEK6
BLK	DYRK4	HPK1(MAP4K1)	NEK7
BMPR2	EGFR	IGF1R	NEK9
BMX	EGFR[A763_Y764insFQEA]	IKK-alpha	NPM1-ALK
BRAF	EGFR[d746-750 T790M C797S]	IKK-beta	p38 $\alpha$ (MAPK14)
BRAF[V600E]	EGFR[D770_N771insNPG]	IKK $\epsilon$ (IKBKE)	p38 $\beta$ (MAPK11)
BRK (PTK6)	EGFR[T790M C797S L858R]	INSR	p38 $\gamma$ (MAPK12)
BRSK2	EGFR[T790M C797S]	IRAK4	p38 $\delta$ (MAPK13)
BTK	EGFR[C797S]	IRR	p70S6K(RPS6KB1)
CaMK4	EGFR[d746-750]	ITK	PAK1
CDC2/CycB1	EGFR[L858R]	JAK1	PAK2
CDC7/ASK	EGFR [L861Q]	JAK2	PAK3
CDK1/CycA2	EGFR [T790M]	JAK3	PAK4
CDK1/CycE1	EPHA1	JNK1(MAPK8)	PBK
CDK12 wt/CycK	EPHA2	JNK2(MAPK9)	PDGFR $\alpha$ [D842V]
CDK13/CycK	EPHA3	JNK3 (MAPK10)	PDGFR $\alpha$
CDK16/CycY	EPHA4	KDR (VEGFR2)	PDGFR $\beta$
CDK17/p35NCK	EPHA5	KIT	PI3K (p120 gamma)
CDK18/CycY	EPHA6	KIT[T670I]	PIK3CA/PIK3R1
CDK19/CycC	EPHA7	KIT[V559D]	PIK3CB/PIK3R1
CDK2 /CycA2	EPHA8	KIT[D816V]	PIK3CD/PIK3R1

Kinase List ( II )			
CDK2 /CycE1	EPHB1	LCK	PIM1
CDK3 /CycE1	EPHB2	LRRK2[G2019S]	PIM2
CDK4 /CycD3	EPHB3	LRRK2 [I2020T]	PIM3
CDK4/CycD1	EPHB4	LRRK2[R1441C]	PKAC $\alpha$ (PRKACA)
CDK5/p25NCK	FGFR1	LTK	PKC $\alpha$ (PRKCA)
CDK5/p35NCK	FGFR1[V561M]	LYNa	PKD2 (PRKD2)
CDK6/CycD1	FGFR2	LYNb	PLK1
CDK6/CycD3	FGFR2 [V564F]	MAP2K1	PLK2
CDK7/CycH/MAT1	FGFR2 [N549H]]	MAP2K2	PLK3
CDK8/CycC	FGFR3	MAP2K3	PRKCE
CDK9/CycT1	FGFR3[K650E]	MAP2K4	PTC1 (CCDC6-RET)
CHK1(CHEK1)	FGFR4	MAP3K1	PYK2 (PTK2B)
RAF1	RSK3 (RPS6KA2)	TIE2[Y897S]	ZAP70
RET	RSK4 (RPS6KA6)	TIE2[R849W]	GCK
RET[V804L]	SGK	TIE2[Y1108F]	GLK
RET[V804M]	SGK2	TRKA[G595R]	KHS
RET[S891A]	SGK3 (SGKL)	TRKA(NTRK1)	MINK(ZC3)
RET[M918T]	SRC	TRKB(NTRK2)	TNIK(ZC2)
ROCK1	SRM (SRMS)	TRKC (NTRK3)	KRAS G12C
ROCK2	SYK	TSSK1	KRAS G12D
RON (MST1R)	TGF $\beta$ R1 (ALK5)	TXK	KRAS G13D
ROS1	TGF $\beta$ R2	TYK2	CLK1
RSK1 (RPS6KA1)	TGF $\beta$ R1[T204D]	TYRO3	RET[G810R]
RSK2(RPS6KA3)	TIE2[TEK]	YES(YES1)	

